Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Pharma Connect Capital is an early-stage life sciences investment fund based in Groningen, Netherlands. Founded to address the financing gap in early pharmaceutical innovation, the firm focuses on startups in Groningen, Friesland, and Drenthe. The fund primarily targets drug development, drug delivery technologies, biomarkers, and diagnostics, particularly academic concepts and pharmaceutical ideas that require capital to reach proof of concept.
As of January 1, 2025, Pharma Connect Capital is closed for new investments and is concentrating on maturing its existing portfolio. The fund has an initial size of EUR 8 million and emphasizes collaboration with local academic institutions to support innovative pharmaceutical initiatives. The firm has established a strong regional link to the Northern Netherlands' life sciences infrastructure, which enhances its investment strategy.
Pharma Connect Capital specializes in very early-stage investments within the life sciences sector, particularly focusing on drug development, drug delivery technologies, biomarkers, and diagnostics. The firm seeks to support academic and innovative pharmaceutical initiatives, helping them progress to the proof of concept stage. The fund's geographic focus is primarily on the Northern Netherlands, specifically in Groningen, Friesland, and Drenthe.
Investment criteria include a strong emphasis on academic concepts and innovative ideas from pharmaceutical and biotech companies. Pharma Connect Capital aims to back projects that demonstrate potential for significant impact in drug development and delivery. The fund's investment strategy is designed to align with regulatory and quality standards, ensuring that portfolio companies are well-prepared for subsequent funding rounds and market entry.
Pharma Connect Capital's portfolio includes several notable companies in the life sciences sector:
These companies reflect Pharma Connect Capital's commitment to supporting early-stage innovations in drug development and related technologies.
Jan Hendriks — Fund Manager at Pharma Connect Capital. He has extensive experience as a pharma/life-science startup investor and operator. Jan is also the CEO of InnoCore Pharmaceuticals and has held various general, commercial, and R&D management roles in pharmaceutical companies.
Dr. Ton Rijnders — Chairman of the Investment Committee. He plays a crucial role in supporting investment assessments and decision-making processes at Pharma Connect Capital.
Prof. Dr. Pieter de Graeff — Member of the Investment Committee. He contributes his expertise to the evaluation of potential investments and strategic direction of the fund.
Mr. Edward van der Meer — Member of the Investment Committee and managing director of Triade. He is affiliated with UMCG and has experience in valorization, commercialization, foundation, and financing of startups.
Pharma Connect Capital is currently closed for new investments, and therefore, they are not accepting pitches at this time. For any inquiries, founders can reach out via email at info@pharmaconnectcapital.com. When the firm is open to new pitches, it is advisable to include a clear overview of the startup's value proposition, market potential, and alignment with the fund's focus areas in any communications.
As of January 1, 2025, Pharma Connect Capital announced that it is closed for new investments and will focus on maturing its current portfolio. This decision marks a significant shift in the firm's operational strategy, emphasizing the importance of supporting existing portfolio companies.
In January 2024, Pharma Connect Capital was the lead investor in a seed round for Sabiad, highlighting its commitment to supporting innovative startups in the life sciences sector.
What are Pharma Connect Capital's investment criteria?
Pharma Connect Capital focuses on very early-stage investments in the life sciences sector, particularly in drug development, drug delivery technologies, biomarkers, and diagnostics. The firm emphasizes supporting academic concepts and innovative pharmaceutical initiatives.
How can I pitch to Pharma Connect Capital?
Currently, Pharma Connect Capital is closed for new investments, and therefore, they are not accepting new pitches. However, interested founders can reach out via email at info@pharmaconnectcapital.com for any inquiries.
What makes Pharma Connect Capital different from other investors?
Pharma Connect Capital has a strong regional focus on the Northern Netherlands and leverages its connections within the academic and life sciences infrastructure to provide strategic support to its portfolio companies. This unique positioning allows them to assist startups in aligning their development plans with regulatory and quality standards.
What is the typical check size for investments?
Specific check sizes have not been disclosed by Pharma Connect Capital. However, the fund primarily targets very early-stage investments, which typically involve smaller initial funding amounts.
What is the geographic scope of Pharma Connect Capital's investments?
The firm focuses on startups located in Groningen, Friesland, and Drenthe, within the Northern Netherlands. This regional emphasis allows them to support local innovations effectively.
What is Pharma Connect Capital's post-investment involvement like?
Pharma Connect Capital provides strategic support to its portfolio companies, helping them navigate the complexities of drug development and regulatory compliance. The firm works closely with its companies to ensure they are well-prepared for future funding rounds and market entry.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.